INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China

Excerpt from the Press Release:

PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), an emerging biotech company with next-generation technology in vaccines – both preventive and therapeutic, today announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. The Phase 2 clinical trial being conducted in China is independent of the INNOVATE Phase 2/3 clinical trial of INO-4800 being advanced in the U.S. and will enroll approximately 640 participants who are 18 years or older. Advaccine is conducting and funding the Phase 2 trial in China, which is expected to fully enroll by the end of this month.

Dr. J. Joseph Kim, President and CEO of INOVIO, said, “We have accelerated the development of INO-4800, our DNA vaccine candidate for COVID-19, in China by working together and leveraging Advaccine’s expertise with Chinese regulatory authorities and clinical trial management. We are grateful for our collaboration with Advaccine and its founder Dr. Bin Wang, China’s premier DNA vaccine expert and Emeritus Professor from Fudan University. Our teams are pleased with the progress to date and our ability to accelerate our clinical work in China with the goal of developing and delivering a safe, tolerable, effective and lasting vaccine for COVID-19.

Click the button below to continue reading the Press Release:

Continue Reading The Press Release